CMPS News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

CM

Mkt Cap

$1.49B

Volume

2.69M

Next Earnings

November 3rd

Loading chart

CM

CMPSCOMPASS Pathways Plc American Depository Shares

CMPS

Pay with—

Available Balance0.00

CM

Mkt Cap

$1.49B

Volume

2.69M

Next Earnings

November 3rd

Chart Financials Earnings News About Insider Filings

These 3 Psychedelic Stocks Activated After Trump’s Executive OrderTrump's April 2026 executive order supporting psychedelic drugs has boosted the psychedelics industry. The FDA awarded priority vouchers to select companies, accelerating drug review timelines. Three biotech firms—Compass Pathways, AtaiBeckley, and Definium Therapeutics—have seen significant stock surges. While analysts remain bullish with high upside targets, these remain speculative investments with substantial risks.Investing.com · Apr 27, 2026

Wall Street Is Betting on More Than MarijuanaAn executive order fast-tracking psychedelic medicines to market has bifurcated the alternative drug sector. Psychedelic stocks like Compass Pathways and Atai Beckley surged 40% and 20% respectively due to regulatory tailwinds and short squeezes, while mature cannabis operators like Curaleaf and Innovative Industrial Properties are now valued as stable, cash-generating businesses rather than speculative plays.Investing.com · Apr 21, 2026

Why Compass Pathways Stock Rocketed 40% TodayCompass Pathways stock surged over 40% following a White House Executive Order aimed at accelerating approval of psychedelic drug treatments for mental health. The company's COMP360 synthetic psilocybin therapy has completed two positive phase 3 trials for treatment-resistant depression and is now on a faster regulatory track with the FDA.The Motley Fool · Apr 20, 2026

Trump Just Fast-Tracked Psychedelic Treatments: 3 Under-the-Radar Stocks That Could Be About to SoarPresident Trump signed an executive order to fast-track FDA approval of psychedelic treatments for mental disorders, reducing review times from 6-10 months to 1-2 months. The order also allocates $50 million for private sector research. Three biotech companies with breakthrough therapy designations saw significant stock gains following the announcement.The Motley Fool · Apr 20, 2026

The Psychedelic Revolution in Mental HealthcarePsychedelic therapy is emerging as a transformative treatment model for mental health conditions, particularly treatment-resistant depression and PTSD. Unlike daily medications, psychedelic therapy is an interventional approach administered 1-6 times with durable long-term benefits. Companies like Compass Pathways are advancing FDA trials, while the real investment opportunity may lie in the $10,000-$20,000 treatment services rather than just the drugs themselves. Big Pharma remains cautiously interested but not yet aggressively pursuing the space.The Motley Fool · Apr 17, 2026

Psychedelic Medicine Advances: Here Are Five Companies Targeting CNS DisordersThe psychedelic medicine sector is advancing with regulatory momentum, as the first psilocybin compound achieved two positive Phase 3 results in treatment-resistant depression. The DEA increased its 2026 psilocybin production quota by 67%. Five companies—Helus Pharma, Compass Pathways, Relmada Therapeutics, Alto Neuroscience, and Axsome Therapeutics—are progressing clinical programs targeting depression, anxiety, cognitive impairment, bladder cancer, and Alzheimer's agitation.Benzinga · Feb 26, 2026

Why Did Compass Pathways Stock Rocket Higher Today?Compass Pathways stock surged 44% after announcing positive Phase 3 clinical trial results for COMP360, its psilocybin-based treatment for treatment-resistant depression. The company plans to submit a New Drug Application (NDA) to the FDA by the end of 2024, with trials involving over 1,000 participants showing statistically significant and clinically meaningful results.The Motley Fool · Feb 17, 2026

Why Compass Pathways Stock Was a Double-Digit Winner This WeekCompass Pathways, a U.K.-based biotech company focused on psilocybin, has completed dosing in a late-stage clinical trial for its synthesized psilocybin treatment, COMP005. The company is testing the treatment on patients with moderate to severe depression who have not responded to previous treatments. Investors are hopeful for the success of this trial, as the field of psychedelic medicine is seen as having significant potential.The Motley Fool · Apr 25, 2025

Comprehensive Market Analysis of Latest Published Different Types of Depression Reports | DelveInsightThe depression treatment market is experiencing steady growth, driven by rising mental health awareness, increasing prevalence of depression, and advancements in novel therapies. The market is expanding with the introduction of innovative antidepressants, psychedelic-based treatments, and digital therapeutics.GlobeNewswire Inc. · Feb 25, 2025

Compass Pathways to participate in three investor conferences in SeptemberCompass Pathways, a biotechnology company focused on mental health, announced its participation in several investor conferences in September 2024, including fireside chats and investor meetings.GlobeNewswire Inc. · Aug 28, 2024

to start trading

CM

CMPSCOMPASS Pathways Plc American Depository Shares

CMPS

Pay with—

Available Balance0.00

Your PositionYou don't own any CMPS yet.

Related Tickers

Earnings